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Abstract
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Background—Because chronic lymphocytic leukemia (CLL) typically follows an indolent
course, many patients do not need to initiate therapy until they reach a relatively advanced age,
when frailty and reduced organ function can make some of the standard treatments difficult to
tolerate and less effective. However, recent advances in the understanding of CLL biology and the
approval of agents in novel treatment classes have offered significant advances in the management
of the disease.
Methods—The author reviewed current treatment goals in CLL management, including issues
surrounding complete remission (CR) and minimal residual disease (MRD); the findings of trials
of treatments from novel drug classes, primarily kinase inhibitors and monoclonal antibodies; and
current strategies for use of standard and novel therapies for treatment of individuals diagnosed
with CLL, particularly elderly patients.
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Results—Several agents and regimens featuring improved clinical outcomes and tolerability are
now available or in advanced development for the management of CLL patients, including the
elderly and those with high-risk disease. These include ibrutinib, idelalisib plus rituximab, and
obinutuzumab plus chlorambucil.
Conclusion—The availability of Bruton’s tyrosine kinase inhibitors and phosphatidylinositol 3kinase inhibitors and other novel therapies will allow elderly CLL patients to receive more
efficacious treatment with greater tolerability than available with traditional approaches for
management of the disease.

Introduction

Author Manuscript

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western
world, accounting for approximately 30% of all leukemias diagnosed in the United States.
Approximately 14,600 new cases of CLL are expected to be diagnosed in the United States
in 2015.1 CLL primarily affects the elderly, with the majority of patients being > 65 years of
age at diagnosis.2 Following diagnosis, most patients are monitored through a “watch and
wait” approach, and therapy typically is not initiated until symptoms develop.
Manifestations of CLL include fevers, night sweats, weight loss, symptomatic
lymphadenopathy, or bone marrow failure (as evidenced by worsening anemia or
thrombocytopenia).3 By the time most patients require therapy, the majority have multiple
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chronic comorbidities, including hypertension, arrhythmias, renal insufficiency, or other
conditions that limit their quality of life and performance status.4,5 Therefore, patients
typically receive their first therapy at an age when they may be too frail to tolerate a regimen
that may be associated with severe toxicities.
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Over the last decade, the understanding of CLL biology has advanced considerably with the
discovery of chromosomal abnormalities and genetic mutations that contribute to the
heterogeneity of the disorder and help predict its clinical course.6 Similarly, the discovery of
the role of the microenvironment and of the signaling factors that play a key role in CLL
pathogenesis has advanced clinicians’ understanding of the condition and has led to the
development of agents that specifically target dysregulated pathways.7,8 With the approval
of several new targeted agents having unprecedented clinical activity (particularly in patients
with high-risk disease, poor prognostic markers, and inability to tolerate cytotoxic
chemotherapy regimens), a transformation is occurring in the treatment of patients with a
CLL diagnosis.
Because of the aging of the population and increased life expectancy of the elderly, CLL
will likely become a progressively more common cause of morbidity and mortality in older
individuals. The goal of this review is to describe novel treatment approaches by
highlighting agents recently approved by the US Food and Drug Administration (FDA) that
will impact the management of CLL, particularly in the frail and the elderly.

Principles of Chronic Lymphocytic Leukemia Treatment Prognostic Factors
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The clinical course of CLL is heterogeneous, hence the need for staging and prognostic
assessment to determine the anticipated disease course. The prognosis of CLL is affected by
disease stage, the patient’s cytogenetic and molecular profile, and the patient’s functional
ability to tolerate therapy.9 There is no evidence that initiation of therapy for asymptomatic
early-stage disease (Rai 0–2 or Binet A) improves survival. Outside of clinical trials,
treatment of early disease is recommended only if a patient develops B symptoms (fever,
night sweats, unintentional weight loss) or disease progression (eg, worsening
lymphadenopathy or bone marrow failure).
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Unfavorable genomic and molecular features include the presence of unmutated
immunoglobulin heavy chain variable (IGHV) gene, CD38 overexpression, zeta-chainassociated protein kinase (ZAP)-70, and specific chromosomal aberrations, including 11q
deletion, 17p deletion, and the presence of a TP53 mutation. A patient’s molecular profile
affects treatment decisions: for patients with evidence of a 17p deletion. and/or a TP53
mutation, the treatment options are limited. The only FDA-approved agent to treat a 17p
deletion CLL patient, regardless of previous therapy, is the Bruton’s tyrosine kinase (BTK)
inhibitor ibrutinib,10 although other agents have shown clinical activity in this patient
population, including the monoclonal antibody alemtuzumab and the phosphatidylinositol 3kinase delta (PI3Kδ) inhibitor idelalisib.11–13
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Treatment Approaches
Although early intervention is considered crucial in most malignant diseases, this is not the
case in CLL. The lack of evidence that CLL can be cured with currently available modalities
has resulted in a “watch and wait” approach for most patients. Except for allogeneic bone
marrow transplant,14 which is not an option in the majority of individuals aged 70 years and
older, current treatment approaches are not curative. The treatment of asymptomatic earlystage disease is not indicated even in the presence of high-risk disease (such as a 17p
deletion or TP53 mutation). The addition of immunotherapy to combination regimens of
cytotoxic chemotherapy has demonstrated superior response and survival.15 Indeed, because
of treatment advances over the past few decades, CLL patients’ median survival from the
time of diagnosis has increased from 96 months in 1980 to > 120 months in 2002.16

Author Manuscript

Although several treatments are available for CLL, the duration of response and of
progression-free survival (PFS) decreases and the risk of complications increases with every
successive line of treatment (Fig). Therefore, practitioners should employ their clinical
judgment in making treatment decisions, with the goal of achieving the most durable
remission possible with the initial therapy, especially in older individuals, who are more
susceptible to treatment complications and may not tolerate a second treatment regimen.
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A remaining area of treatment controversy is whether minimal residual disease (MRD)
should be pursued in addition to a clinical complete remission (CR). MRD is defined as <
0.1% of leukemic lymphocytes in the bone marrow detected by oligonucleotide polymerase
chain reaction (PCR) and four-color flow cytometry. The absence of MRD after fludarabinebased chemoimmunotherapy is associated with a more prolonged PFS and overall survival
(OS), although outcomes in the setting of novel targeted agents have not yet been
established. The duration of response while using a novel targeted agent may not necessarily
correlate with the depth of response, and a remission may not be necessary to obtain durable
clinical benefit for as long as continuous therapy is offered.
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Whereas in younger or fit patients the aim may be to achieve a CR and MRD negativity with
the use of chemoimmunotherapy, this approach traditionally has been poorly tolerated in
patients with multiple comorbidities. For elderly individuals, early detection of absence of
MRD may prompt early chemoimmunotherapy cessation, thereby substantially reducing the
risk of treatment-related toxicity.17 Alternatively, frail patients may benefit primarily from a
low-intensity approach in which the therapeutic endpoint is not CR or MRD, but rather
duration of remission, tolerability, and quality of life. There is a clear need for greater
representation of elderly and frail patients in randomized CLL clinical trials to assess the
therapeutic goals of CR and MRD negativity in this patient population, particularly in the
era of kinase inhibitor therapy. MRD negativity should be regarded as a treatment goal only
in the setting of a clinical trial.

Medications
Table 1 contains a list of the most common medications utilized in the treatment of CLL.
Outlined here are targeted and immune-directed therapies that are impacting the way
clinicians treat CLL.
Cancer Control. Author manuscript; available in PMC 2016 October 01.
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The current CLL treatment paradigm is evolving based on the understanding of the disease’s
pathophysiology. The B-cell receptor (BCR) regulates fundamental proliferation and
survival mechanisms for malignant B-cells. These functions are mediated by signals that are
transmitted intracellularly downstream through several kinases, including Lyn kinase, spleen
tyrosine kinase (SYK), PI3K, BTK, and others. Targeting these kinases, in particular the
BTK and the PI3K signaling pathways, has shown remarkable clinical activity in patients
with CLL and with other B-cell malignancies.7,18
Ibrutinib
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BTK is a cytoplasmic tyrosine kinase involved in signaling of the BCR and chemokine
receptors. Ibrutinib is the first-in-class oral agent targeting the BTK pathway by forming a
covalent bond with its active site, cysteine-481. It achieves target inhibition with once-daily
oral dosing. In vitro and in vivo models demonstrate that ibrutinib inhibits survival,
proliferation, and migration of CLL cells.18
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Ibrutinib inhibits secretion of CCL3 and CCL4 by CLL cells, and at least part of this process
occurs in a BCR-dependent manner.19 Use of ibrutinib (or any agent targeting the B-cell
receptor pathway) results in rapid lymphocytosis accompanied by a marked reduction in
lymphadenopathy, a “redistribution” phenomenon that is reversible upon temporary
discontinuation of the targeted agent.18 In a phase 1b/2 clinical trial, treatment with ibrutinib
monotherapy in patients with relapsed or refractory CLL resulted in an overall response rate
(ORR) of 71% and durable remissions (estimated PFS at 26 months: 75%) for all patient
groups, including elderly patients and those with high-risk disease.20 In the phase 3
RESONATE trial for patients with relapsed or refractory CLL, ibrutinib was evaluated
against ofatumumab. Ibrutinib demonstrated improved PFS and OS vs ofatumumab, with
outcomes independent of 17p deletion status.21
Minimal toxicities reported with ibrutinib included diarrhea, grades 1 and 2 pyrexia and
infections, and grades 1 and 2 bleeding events.
Idelalisib
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Idelalisib is a first-in-class inhibitor of PI3K, which plays a pivotal role in signal
transduction involved in the growth, proliferation, differentiation, and survival of B-cells. A
randomized, double-blind, placebo-controlled phase 3 trial of rituximab with or without
idelalisib in CLL patients was discontinued early on the recommendation of an independent
data and safety monitoring board after the combination regimen demonstrated clear
superiority vs the monotherapy arm. The reported ORR was 81% in patients receiving
idelalisib plus rituximab vs 13% in patients receiving rituximab plus placebo.22 The most
common adverse events associated with idelalisib included pyrexia, fatigue, and nausea. It is
important to note that, although the drug was initially well tolerated, a severe noninfectious
secretory diarrhea (grade 3 or 4) and/or colitis was reported as a late toxicity in 14% of study
participants.23
Both ibrutinib and idelalisib have shown clinical activity in deletion 17p and/or in TP53mutated disease.10,13 Because of their excellent tolerability and effectiveness, both ibrutinib
and idelalisib appear particularly suitable for the treatment of elderly individuals. Ongoing
Cancer Control. Author manuscript; available in PMC 2016 October 01.
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trials are evaluating these drugs’ usefulness both alone and in various combinations as
frontline CLL treatment in frail and elderly patients.24,25
Obinutuzumab
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Rituximab, ofatumumab, and obinutuzumab are monoclonal antibodies directed at the CD20
antigen and are used mainly in combination with other chemotherapeutic agents. Except for
the possibility of severe or life-threatening infusion reactions and viral hepatitis reactivation,
these agents are generally well tolerated. The most promising of these monoclonal
antibodies that target CD20 is obinutuzumab. Obinutuzumab differs from previous antiCD20 monoclonal antibodies with respect to its glyco-engineered crystallizable fragment
(Fc) region and its type 2 CD20-binding mode. Glyco-engineering increases the binding
affinity of the Fc portion of obinutuzumab to the Fcγ receptor III on innate immune effector
cells (such as neutrophils, natural killer cells, and macrophages); in turn, this results in
improved antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular
phagocytosis.26 Obinutuzumab is indicated in combination with chlorambucil for use in
treatment-naive CLL patients, based on the findings of a large phase 3 trial in which
treatment- naive patients were randomized to receive either chlorambucil or chlorambucil
plus rituximab or chlorambucil plus obinutuzumab.27 In elderly (median age 73 years)
patients with multiple debilitating comorbidities, the combination of obinutuzumab with
chlorambucil was associated with a significant and clinically meaningful prolongation of
PFS, increased CR, and an increased rate of MRD negativity, compared with the results
obtained with the rituximab plus chlorambucil combination. Moreover, treatment with
obinutuzumab plus chlorambucil resulted in a significant OS benefit compared with
chlorambucil monotherapy, suggesting that the induction of deeper remissions (ie, MRD
negativity) could translate into a survival advantage even in frail patients.26 Combination
studies of obinutuzumab with the novel inhibitors of B-cell receptors are planned.
Alemtuzumab
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Alemtuzumab is a monoclonal antibody directed against the CD52 antigen and is approved
for use as monotherapy in CLL. Data from clinical trials suggest that the drug has good
clinical activity in patients with minimal nodal disease and in those with 17p or 11q
deletions. Until the introduction of ibrutinib, alemtuzumab was the most commonly used
agent in patients with 17p deletion or TP53-mutated disease.11,12 Alemtuzumab may still
represent an option for patients whose CLL has failed to respond to other treatments.
Alemtuzumab can have substantial toxicity, including fevers, pancytopenia, and severe viral
or fungal infections, particularly reactivation of cytomegalo-virus. Concerns about its
infectious complications contributed to its limited use in CLL patients. The drug was
withdrawn from the US and European markets, but it is still available through manufacturersponsored patient access programs.
Lenalidomide
Although not FDA-approved, lenalidomide is another targeted agent that has shown
promising clinical activity in CLL patients.28,29 Unfortunately, the frontline study evaluating
lenalidomide vs chlorambucil in CLL patients older than 65 years (ORIGIN trial,
NCT00910910) had to be halted due to safety concerns. The patients randomized to
Cancer Control. Author manuscript; available in PMC 2016 October 01.
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lenalidomide had a 92% increased risk for death compared with the patients receiving
chlorambucil. Adverse effects of lenalidomide use include neuropathy, thrombocytopenia,
and thrombotic events. At this time, the role of lenalidomide in the management of CLL is
not well defined because of the availability of multiple other treatment options.
Treatment Strategies—Current recommended initial treatment of CLL includes a
combination of cytotoxic chemotherapy plus a CD20 monoclonal antibody in young patients
or fit elderly patients. The most common regimens are (1) fludarabine, cyclophosphamide,
and rituximab (FCR) and (2) bendamustine plus rituximab (BR). Recently, a large European
phase 3 trial demonstrated the PFS superiority of FCR vs BR in patients with unmutated
IGHV.30
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In addition, FCR was associated with increased rates of complete remission and MRD
negativity; in the setting of chemoimmunotherapy, this finding correlates with longer
remission duration and possibly survival. The investigators recommended that, in fit patients
without 17p deletion or TP53 mutation, FCR should be the preferred frontline treatment. It
is important to note that the median age of the patients in both arms was 61 years, which is a
decade younger than the median age at CLL diagnosis and the patients that participated in
the trials were fit with few comorbidities. The difference in PFS was not statistically
significant between the arms in patients ≥ 65 years old, suggesting that fit elderly patients
may benefit from treatment with BR rather than FCR. FCR use was associated with
increased risk of neutropenia, febrile neutropenia, and other complications that may be
particularly severe and potentially lethal in older individuals (treatment- related mortality:
3.9% [FCR] vs 2.1% [BR]).
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Despite the availability of combination regimens like FCR and BR, until very recently the
frontline management of older and unfit CLL patients had been limited to the use of
chlorambucil or rituximab monotherapy. The use of chemoimmunotherapy regimens was
not an option until the recent report by Goede et al.27 The pivotal phase 3 study
demonstrated the superiority of the combination of chlorambucil plus obinutuzumab against
chlorambucil alone in terms of PFS, CR, and OS. This registrational trial did not include age
as an eligibility criterion; rather, it used the presence of a high cumulative illness rating scale
(CIRS) score, which describes functional comorbidity and/or the presence of impaired renal
function (patients of any age with a glomerular filtration rate of 30 mL to 69 mL/min). This
study represents a major advance in the treatment of elderly patients with CLL who lack a
17p deletion and establishes a standard of care for the elderly and for frail patients with
multiple medical conditions.
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In another important phase 3 study evaluating the use of chemoimmunotherapy in elderly
patients (median age 69 years) with multiple comorbidities, Hillmen et al31 compared
chlorambucil in combination with the anti-CD20 monoclonal antibody ofatumumab vs
chlorambucil alone in patients for whom fludarabine therapy was inappropriate based on age
or comorbidities. Patients receiving the combination treatment experienced a substantial
improvement in PFS.

Cancer Control. Author manuscript; available in PMC 2016 October 01.

Barrientos

Page 7

Author Manuscript
Author Manuscript

The only agent currently approved for use in patients with a 17p deletion is ibrutinib.
Although idelalisib (in combination with rituximab) has not been approved for this
particular indication, clinical trials have shown clinical activity in patients with a 17p
deletion,13 and this would be a reasonable treatment approach in patients unable to tolerate
ibrutinib therapy. For eligible patients, evaluation for allogeneic bone marrow
transplantation is recommended in any patient with high-risk disease. Clinicians should
make a decision only after carefully deliberating the advantages and disadvantages of
continued therapy vs stem cell transplant. Conditions potentially favoring transplant include
younger age and availability of a donor for a high-risk-disease patient carrying the 17p
deletion or 11q deletion.32 The longest follow-up data of ibrutinib-treated patients having a
17p deletion (with a median of four prior therapies) reported a median PFS of 28 months. It
is important to recognize that PFS with ibrutinib varies by interphase cytogenetic
abnormality, with 17p deletion patients having a 30-month estimated PFS rate of 48% (less
than the 74% rate observed for 11q deletion patients and the 87% rate observed when neither
of these genomic aberrations is present).33 More recent data suggest that complex karyotype
may also be a risk factor.34,35 In fact, most patients with relapsed or refractory CLL who
discontinued ibrutinib early were difficult to treat and had poor outcomes with relatively
short survival.33,34 Published data regarding the sequencing of these new agents are
relatively limited and anecdotal. Until greater clarity develops regarding which newer agents
can be recommended as salvage therapy in patients whose disease progressed following
ibrutinib therapy, transplantation will remain an important consideration for fit, transplanteligible patients with a deletion 17p (or other high-risk characteristic), as transplant offers a
potentially curative therapy.
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For previously treated patients, ibrutinib as a single agent proved significantly more
effective than ofatumumab in the open-label phase 3 RESONATE study in CLL patients
with measurable nodal disease who were not eligible for treatment with purine analog-based
therapy and who had received ≥ 1 prior therapies.21 The outcomes of the 391 patients
(median age 67 years) with relapsed CLL who participated in this trial were recently
updated. The ORR with ibrutinib was 90% vs 25% with ofatumumab; PFS was not reached
at 15 months with ibrutinib and was reached at 8.1 months with ofatumumab.36 With longer
follow-up, ibrutinib-treated patients maintained the improved OS. No significant difference
in 12-month PFS was observed in ibrutinib-treated patients with or without 17p deletion or
for those who developed lymphocytosis compared with those without lymphocytosis. These
dramatic results, which did not appear to be influenced by patient age and were achieved
with minimal toxicity, have established ibrutinib as the preferred second-line agent in CLL.
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In another pivotal phase 3 study in patients ineligible for cytotoxic therapy, the combination
of idelalisib plus rituximab proved superior to rituximab alone in relapsed CLL. Of the 220
patients enrolled, 78% were 65 years and older.22 The median PFS duration was 5.5 months
for rituximab and > 15 months for idelalisib plus rituximab; OS was also greater with
combination therapy (92% in the idelalisib plus rituximab group vs 80% in the rituximab
plus placebo group at 12 months). The results were independent of patient age or 17p
deletion.13 The combination of idelalisib plus rituximab was well tolerated; adverse events
reported included diarrhea, grades 1 and 2 pyrexia and infections, and grades 1 and 2
transaminitis.
Cancer Control. Author manuscript; available in PMC 2016 October 01.
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As described, a number of new therapeutic options are available in the frontline and secondline (or beyond) settings for CLL patients (Table 2). These novel agents are associated with
prolonged survival in CLL patients, including those with high-risk disease who historically
have had poor survival rates. These targeted therapies are particularly promising for patients
70 years and older, whose numbers will progressively increase and who already represent
the largest cohort of CLL patients.
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Management of Older Individuals with Chronic Lymphocytic Leukemia—Based
on the findings reviewed in this article, this author proposes that older CLL patients or
patients with comorbidities should be considered for participation in a clinical trial if
available or treated according to the therapy recommendations outlined in Tables 2 and 3.
All individuals 70 years of age and older should undergo a comprehensive geriatric
assessment before initiation of therapy to estimate cancer-independent mortality risk and
tolerance of chemotherapy and to identify conditions that may interfere with the treatment.
These may include the potential for drug-drug interactions due to polypharmacy, poor access
to nutrition, inadequate social support, depression, memory disorders, and other coexisting
illnesses or conditions that may necessitate interventions, as these may affect the therapeutic
effect of the proposed treatment plan. It is very important to individualize the patient’s
therapy based on the specific clinical presentation.
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In the near future, novel agents such as those discussed in this article may be shown to have
comparable or even improved outcomes with greater tolerability compared with FCR. Two
large cooperative group trials in the United States are currently evaluating whether the
rational use of targeted agents such as ibrutinib in the frontline setting is superior in terms of
duration of remission, survival, quality of life, and tolerability in fit patients up to the age of
70 years (FCR vs ibrutinib plus rituximab [NCT02048813]) and in older patients with
comorbidities (BR vs ibrutinib vs ibrutinib plus rituximab [NCT01886872]). Several other
on- going clinical trials are specifically accruing patients older than 65 years with the goal of
improving current outcomes (more information can be obtained at www.clinicaltrials.gov).
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Most importantly, in addition to the recently ap proved agents, an array of promising new
therapeutic interventions are undergoing evaluation in clinical trials including secondgeneration BTK or PI3Kδ inhibitors, anti-apoptotic inhibitors, targeted tumor-specific
cellular therapies, and others. The rational design of targeted agents appears to address
elderly patients’ unmet needs with respect to improved efficacy and tolerability. With the
introduction of these agents into the CLL armamentarium, clinicians may be able to exploit
combination strategies that enable patients to achieve longer remissions, potentially altering
the natural course of the disease. In fact, it may be possible to envision a future in which
patients can receive chemotherapy-free treatment that is potentially curative.
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Fig.

Regimens for chronic lymphocytic leukemia can have substantial toxicity and generally
become less effective with recurrent treatment.
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Table 1

Author Manuscript

Medications Approved in the United States for the Treatment of Chronic Lymphocytic Leukemia
Drug Class
Alkylating Agents

Purine Analogues

Monoclonal Antibodies

BTK Inhibitor

PI3Kδ Inhibitor

Chlorambucil

Fludarabine

Rituximab* (in combination with fludarabine and
cyclophosphamide)

Ibrutinib

Idelalisib (in
combination with
rituximab)

Cyclophosphamide

Pentostatin

Ofatumumab (as monotherapy or in combination
with chlorambucil)

Bendamustine

Obinutuzumab (in combination with
chlorambucil)
Alemtuzumab

BTK = Bruton’s tyrosine kinase, PI3Kδ = phosphatidylinositol-3-kinase delta.
*

Also used in combination with bendamustine (BR regimen), but not FDA-approved for this combination
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Table 2

Author Manuscript

Frontline Regimens for Chronic Lymphocytic Leukemia

Author Manuscript

Patient Population

Treatment Options

Patients < 70 years of age, or older patients without significant
comorbidities and without del(17p)

Fludarabine + cyclophosphamide + rituximab (FCR)
Bendamustine ± rituximab (BR)
Fludarabine + rituximab (FR)
Pentostatin + cyclophosphamide + rituximab (PCR)
Obinutuzumab + chlorambucil
Ofatumumab + chlorambucil

Patients ≥ 70 years of age or younger patients with comorbidities without
del(17p)

Obinutuzumab + chlorambucil
Ofatumumab + chlorambucil
Bendamustine ± rituximab (BR)
Cyclophosphamide ± rituximab ± corticosteroids
Fludarabine ± rituximab (FR)
Dose-reduced fludarabine + cyclophosphamide + rituximab (FCR)
Chlorambucil ± rituximab

Patients with significant comorbidities who are unable to tolerate purine
analogues

Obinutuzumab + chlorambucil
Ofatumumab + chlorambucil
Chlorambucil ± rituximab

Patients with del(17p)

Ibrutinib
Idelalisib + rituximab
Clinical trial
Alemtuzumab
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Table 3

Author Manuscript

Salvage Therapy for Relapsed Chronic Lymphocytic Leukemia

Author Manuscript

Patient Population

Treatment Options

Patients with short response to initial therapy who
are < 70 years of age

Clinical trial
Ibrutinib
Idelalisib + rituximab
Fludarabine + rituximab ± cyclophosphamide (if no prior FCR)
Pentostatin + rituximab ± cyclophosphamide (if no prior FCR)
Bendamustine ± rituximab
Ofatumumab
High-dose methylprednisolone + rituximab
Lenalidomide ± rituximab
Alemtuzumab ± rituximab
OFAR (oxaliplatin, fludarabine, cytarabine, rituximab)
R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone)

Patients with short response to initial therapy who
are aged ≥ 70 years without del(17p)

Clinical trial
Ibrutinib
Idelalisib + rituximab
Bendamustine ± rituximab
Ofatumumab
High-dose methylprednisolone + rituximab
Alemtuzumab ± rituximab

Patients with del(17p)

Clinical trial
Ibrutinib
Idelalisib + rituximab
High-dose methylprednisolone + rituximab
Alemtuzumab ± rituximab
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